CULLINAN THERAPEUTICS, INC. (CGEM) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth No data.
7/29
1.2 / 5 stars
All 29 Win/Lose results and 91 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 1 losses, 8 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/1 |
WinCGEM / S&P 28.15% / 15.20% |
No dataCGEM / S&P / 15.00% |
No dataCGEM / S&P / 50.40% |
| 2026-Q11/1 |
WinCGEM / S&P 37.29% / -4.33% |
No dataCGEM / S&P / 11.30% |
No dataCGEM / S&P / 27.70% |
| 2025-Q41/1 |
WinCGEM / S&P 74.54% / 2.65% |
No dataCGEM / S&P / 9.00% |
No dataCGEM / S&P / 13.40% |
| 2025-Q30/1 |
LoseCGEM / S&P -21.25% / 8.12% |
No dataCGEM / S&P / 4.61% |
No dataCGEM / S&P / 13.45% |
| 2025-Q20/1 |
LoseCGEM / S&P -0.53% / 10.94% |
No dataCGEM / S&P / 4.83% |
No dataCGEM / S&P / 10.63% |
| 2025-Q10/1 |
LoseCGEM / S&P -37.85% / -4.27% |
No dataCGEM / S&P / 4.98% |
No dataCGEM / S&P / 10.57% |
| 2024-Q40/1 |
LoseCGEM / S&P -27.24% / 2.41% |
No dataCGEM / S&P / 5.25% |
No dataCGEM / S&P / 6.15% |
| 2024-Q30/2 |
LoseCGEM / S&P -4.01% / 5.89% |
No dataCGEM / S&P / 5.89% |
LoseCGEM / S&P -23.86% / 6.11% |
| 2024-Q20/2 |
LoseCGEM / S&P 2.35% / 4.28% |
No dataCGEM / S&P / 5.38% |
LoseCGEM / S&P -8.93% / 5.12% |
| 2024-Q11/2 |
WinCGEM / S&P 67.22% / 10.56% |
No dataCGEM / S&P / 5.71% |
LoseCGEM / S&P -354.47% / 5.59% |
| 2023-Q41/2 |
WinCGEM / S&P 12.60% / 11.69% |
No dataCGEM / S&P / 6.81% |
LoseCGEM / S&P -255.04% / 7.78% |
| 2023-Q30/2 |
LoseCGEM / S&P -15.89% / -3.27% |
No dataCGEM / S&P / 7.52% |
LoseCGEM / S&P -269.55% / -5.03% |
| 2023-Q20/2 |
LoseCGEM / S&P 5.18% / 8.74% |
No dataCGEM / S&P / 9.50% |
LoseCGEM / S&P -243.59% / -8.57% |
| 2023-Q10/2 |
LoseCGEM / S&P -3.03% / 7.50% |
No dataCGEM / S&P / 10.77% |
LoseCGEM / S&P -168.72% / -15.69% |
| 2022-Q40/2 |
LoseCGEM / S&P -17.71% / 7.56% |
LoseCGEM / S&P -100.00% / 11.88% |
No dataCGEM / S&P / -17.99% |
| 2022-Q31/1 |
WinCGEM / S&P 0.00% / -4.88% |
No dataCGEM / S&P / 13.47% |
No dataCGEM / S&P / -1.41% |
| 2022-Q21/1 |
WinCGEM / S&P 22.45% / -16.10% |
No dataCGEM / S&P / 13.71% |
No dataCGEM / S&P / 11.04% |
| 2022-Q10/1 |
LoseCGEM / S&P -32.15% / -4.60% |
No dataCGEM / S&P / 15.97% |
No dataCGEM / S&P / 42.23% |
| 2021-Q40/1 |
LoseCGEM / S&P -31.63% / 11.03% |
No dataCGEM / S&P / 15.00% |
No dataCGEM / S&P / 96.40% |
| 2021-Q30/1 |
LoseCGEM / S&P -12.35% / 0.58% |
No dataCGEM / S&P / 10.77% |
No dataCGEM / S&P / 69.42% |
| 2021-Q20/1 |
LoseCGEM / S&P -38.20% / 8.55% |
No dataCGEM / S&P / 6.58% |
No dataCGEM / S&P / 51.81% |
| 2021-Q10/0 |
No dataCGEM / S&P / 6.17% |
No dataCGEM / S&P / -1.06% |
No dataCGEM / S&P / 7.39% |
| 2020-Q40/0 |
No dataCGEM / S&P / 12.15% |
No dataCGEM / S&P / -3.72% |
No dataCGEM / S&P / -33.42% |
| 2020-Q30/0 |
No dataCGEM / S&P / 8.93% |
No dataCGEM / S&P / -2.04% |
No dataCGEM / S&P / -27.10% |
| 2020-Q20/0 |
No dataCGEM / S&P / 20.54% |
No dataCGEM / S&P / -0.46% |
No dataCGEM / S&P / -27.11% |
| 2020-Q10/0 |
No dataCGEM / S&P / -19.60% |
No dataCGEM / S&P / 3.47% |
No dataCGEM / S&P / -14.75% |
| 2019-Q40/0 |
No dataCGEM / S&P / 9.07% |
No dataCGEM / S&P / 5.36% |
No dataCGEM / S&P / 2.99% |
| 2019-Q30/0 |
No dataCGEM / S&P / 1.70% |
No dataCGEM / S&P / 5.02% |
No dataCGEM / S&P / 0.21% |
| 2019-Q20/0 |
No dataCGEM / S&P / 4.30% |
No dataCGEM / S&P / 6.64% |
No dataCGEM / S&P / 8.65% |
| 2019-Q10/0 |
No dataCGEM / S&P / 13.65% |
No dataCGEM / S&P / 8.12% |
No dataCGEM / S&P / 14.29% |
| 2018-Q40/0 |
No dataCGEM / S&P / -13.52% |
No dataCGEM / S&P / 9.05% |
No dataCGEM / S&P / 18.23% |
| 2018-Q30/0 |
No dataCGEM / S&P / 7.71% |
No dataCGEM / S&P / 10.21% |
No dataCGEM / S&P / 19.06% |
| 2018-Q20/0 |
No dataCGEM / S&P / 3.43% |
No dataCGEM / S&P / 9.03% |
No dataCGEM / S&P / 14.46% |
| 2018-Q10/0 |
No dataCGEM / S&P / -0.76% |
No dataCGEM / S&P / 7.68% |
No dataCGEM / S&P / 12.46% |
| 2017-Q40/0 |
No dataCGEM / S&P / 6.64% |
No dataCGEM / S&P / 7.03% |
No dataCGEM / S&P / 13.82% |
| 2017-Q30/0 |
No dataCGEM / S&P / 4.48% |
No dataCGEM / S&P / 5.68% |
No dataCGEM / S&P / 17.57% |
| 2017-Q20/0 |
No dataCGEM / S&P / 3.09% |
No dataCGEM / S&P / 4.83% |
No dataCGEM / S&P / 17.74% |
| 2017-Q10/0 |
No dataCGEM / S&P / 6.07% |
No dataCGEM / S&P / 3.67% |
No dataCGEM / S&P / 13.32% |
| 2016-Q40/0 |
No dataCGEM / S&P / 3.82% |
No dataCGEM / S&P / 2.09% |
No dataCGEM / S&P / 7.05% |
| 2016-Q30/0 |
No dataCGEM / S&P / 3.85% |
No dataCGEM / S&P / 0.20% |
No dataCGEM / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CGEM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 199.73% | 20.78% |
| Annualized return | 199.73% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CGEM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -21.56% | 83.14% |
| Annualized return | -4.74% | 12.86% |
10Y · 2021-01-08 to 2026-08-27
| Metric | CGEM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -24.44% | 319.30% |
| Annualized return | -2.76% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |